Novel Cyclized Hexapeptide-9 Outperforms Retinol Against Skin Aging: A Randomized, Double-Blinded, Active- and Vehicle-Controlled Clinical Trial.
Summary
In a double-blind, active- and vehicle-controlled trial over 56 days, cyclized hexapeptide-9 significantly improved the number, area, and roughness of crow’s feet and forehead wrinkles, outperforming retinol on most outcomes. Effects appeared to augment over time, supporting peptide cyclization as a viable anti-aging strategy.
Key Findings
- CHP-9 significantly reduced number, area, and roughness of crow’s feet and forehead wrinkles; retinol improved fewer parameters.
- Magnitude of effect favored CHP-9 over retinol on most outcomes except crow’s feet roughness.
- Time-dependent augmentation observed with continued CHP-9 use over 56 days.
Clinical Implications
CHP-9 may serve as an effective alternative for patients intolerant to retinoids or seeking improved efficacy with potentially favorable tolerability; integration into long-term regimens merits consideration.
Why It Matters
This trial provides head-to-head evidence that a next-generation peptide can surpass retinol on key clinical wrinkle metrics, potentially reshaping first-line topical anti-aging approaches.
Limitations
- Sample size not reported in abstract and short 56-day duration
- Safety/tolerability outcomes not detailed in the abstract
Future Directions
Confirm long-term safety and durability, define mechanisms and optimal concentrations, and assess performance across diverse skin types and phototypes.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized, double-blind, active- and vehicle-controlled clinical trial
- Study Design
- OTHER